Confirmation: Medtron executive leaves

On December 23rd, the day after Medtron's senior management left, Sean Salmon, Executive Vice President and President of Medtron Diabetes Operations, was appointed Executive Vice President and President of Cardiovascular Products, effective January 1, 2021, according to the Associated Press.
salmon will continue to lead the diabetes operations and serve on the company's executive committee.
Salmon replaces Mike Coyle, who will leave Medtron on December 31st to take over as chief executive of a publicly traded company.
reported that Salmon joined Medtron in 2004 and has held senior management positions in the cardiovascular field for 15 years, including leading the coronary artery and renal neurology, excrement, cardiac surgery and heart structure business, before being appointed leader of Medtron Diabetes and a member of Medtron's Executive Committee in 2019.
During his tenure in the cardiovascular department, Salmon led Medtronic's drug deseeding stents, commercialized a variety of product innovations through catheter aortic valve replacement (TAVR), and revitalized Medtronic's kidney neurodestructive clinical program.
It is understood that Medtron is undergoing major business restructurings in the near future, and on September 14th Seber Blue Devices confirmed from authoritative sources that Medtron plans to split its existing business into 20 business units, while Medtron will simplify its operating model in the coming months.
also confirmed that the current adjustment has begun in September, BU changed to OU.
early September, according to Bloomberg News, Medtron's CEO announced that he would restructure the company to boost revenue capacity, and Medtron developed a strategy of "partial adjustment" and "overall restructuring" to its strengths.
the scope and focus of the two, two-way reform is Medtron's future plan.
November 27, 2020 China Medical Device Industry Summit and 2020 National Pharmaceutical Device Ecological Conference was held in Wuhan.
, Senior Vice President and President of Greater China, said at the meeting that Medtron will have four major strategies for its future development.
First, to accelerate market access, so that new therapies and new products to promote clinical use, second, to deepen market development, the innovation center built in Chengdu will play its due role in the development of the western industry, the third is to promote local manufacturing, so that the entire industry chain to achieve localization, accelerate the combination of clinical and innovative, and fourth, let the company's value chain layout and the external industry ecological convergence, and jointly empower local innovation.
's board of directors has named Jennifer Honeycutt as executive vice president of the company and is responsible for Beckman Coulter's life sciences and integrated DNA technology, according to the agency. Technologies, Leica Microsystems, Molecular Devices, Pall, and related clinical and scientific mass spectrometry services (Phenomenex and SCIEX Businesses).
the new appointment, which will take effect in January 2021, will see Honey carter become the company's chief executive.
it is understood that when Danaher acquired Hach in 1999, Honey carter joined Danaher and went on to take up a number of positions and gradually take over general management positions.
began his career at Hach in 1991 as a research chemist.
, on May 6 this year, Danaher's official website announced that the company's CEO would be handed over.
September 1, 2020, following the retirement of Thomas P. Joyce Jr., The chief executive officer of Danaher, Rainer M. Blair, the current executive vice president, will succeed him as president and CEO of Danaher.
Joyce will remain in Danaher as a senior adviser until 28 February 2021.
1989, Thomas P. Joyce Jr. began his career in Danaher, serving as President and CEO since September 2014.
understand that in 2018 Danaher's business has four major segments: dentistry, life sciences, diagnostics and environment and applications, accounting for 14%, 33%, 31% and 22% of total revenue, respectively.
total revenue for 2018 is about $19.9 billion.
2019, Danaher, one of the four main businesses of the dental company, split up and made an initial public offering in the United States.
2019, Danaher's revenue reached $17.91 billion, down 9.96 percent from a year earlier, according to the company's annual report.
recently reported third-quarter 2020 results, with quarterly sales of $5,883 million, up 34% year-on-year and net profit of $842 million, up 30% year-on-year.
of domestic well-known machinery enterprises resigned in addition to Medtron and Danaher, a number of domestic machinery enterprises have also recently seen changes in senior management.
December 19, Meikang Bio announced that the company's fourth board of directors agreed to appoint Yu Jihuasheng as the general manager of the company, agreed to appoint Mr. Yuan Chao, Ms. Xiong Huiping, Mr. Fang Liang, Mr. Shen Min as the company's deputy general manager.
, Mr. Yuan Chao was appointed as the Company's Finance Director, Ms. Xiong Huiping was appointed Secretary of the Company's Board of Directors, and Ms. Yu Xiaoxuan was appointed as the Company's Securities Representative.
It is understood that Meikang Bio is mainly engaged in in-body diagnostic products research and development, production, sales and medical diagnostic services, the main business includes in-body diagnostic reagents and instruments, independent third-party medical diagnostic services (regional medical testing and sharing center), reagent raw materials.
on September 24, Xinhua Medical announced that it had received the resignation application of Mr. Xu Shangfeng, Chairman of the Company, who had applied to resign as Chairman and Director of the 10th Board of Directors, Chairman and Member of the Strategy Committee, member of the Audit Committee, member of the Remuneration and Assessment Committee and member of the Nomination Committee because of the retirement age.
, Xinhua Medical held the fifth meeting of the 10th Board of Directors, after the voting of the participating directors, elected Mr. Wang Yuquan as the chairman of the company.
August 12, Beijing Lidman announced that the company's board of directors received a written resignation report from The Chairman, Mr. Lin Wei.
reasons for the transfer of work, Mr. Lin requested to resign as chairman and director of the company, and at the same time resigned as convenor of the strategic committee of the board of directors, and resigned from any position of the company.
August 11, Fish Leap Medical announced that the board of directors received a written resignation report from Mr. Zhao Chunsheng, Vice President (Deputy General Manager) of the Company, who requested his resignation as Vice President (Deputy General Manager) of the Company for personal reasons.
Mr. Zhao Chunsheng resigns, he will no longer hold any positions in the company.
January 11, Lanfan Medical announced that it had received a written resignation report from the company's director and president, Mr. Li Rongrong.
Mr. Li Will resign as a director, president and member of the Strategic Committee of the Board of Directors at the age of 70, and resign from his position in a subsidiary, after which he will not hold any position in the Company.
, the board of directors has agreed to appoint Ms. Liu Wenjing as president of the company.
understood that Ms. Liu Wenjing served as General Manager of BlueFan Medical from 2005 to April 2013 and As Chairman since April 2013.
。